A Phase 3 interventional study of Cenestin 0.3 mg Tablets and Placebo in Hot Flashes, sponsored by Duramed Research. Completed at 49 sites in United States. Open to female participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-07-03.
Sponsored by Duramed Research · Phase 3, Interventional, and Treatment
This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.
The overall study duration will be approximately 16 weeks. After a screening/baseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or Cenestin 0.3mg tablets
285 studies on the registry are indexed under Hot Flashes; 50 are open to participants now.
This study's planned enrollment of 400 is above the median of 90 across 255 interventional studies indexed under Hot Flashes.
Browse Hot Flashes studies →Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Cenestin 0.3 mg Tablets
Other: Placebo
1 tablet daily
Also known as: Synthetic conjugated estrogens, A
1 tablet daily
Also known as: Placebo tablets
Mean change in average frequency of moderate to severe hot flashes
Time frame: Baseline to Day 28 and to Day 84
Mean change in severity of moderate to severe hot flashes
Time frame: Baseline to Day 28 and to Day 84
Safety and tolerability of Cenestin 0.3mg
Time frame: Throughout study
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duramed Research